BSAM
NBIX icon

Blue Sky Asset Management’s Neurocrine Biosciences NBIX Stock Holding History

Blue Sky Asset Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-22,710
Closed -$1.04M – 101
2017
Q2 		$1.04M Sell
22,710
-5,206
-19% -$253K 0.57% 38
2017
Q1 		$1.21M Buy
+27,916
New +$1.2M 0.73% 22

Other funds holding NBIX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Blue Sky Asset Management's NBIX Position: Q3 2017 in Review

Blue Sky Asset Management sold out of Neurocrine Biosciences (NBIX) in Q3 2017, closing a stake of 22,710 shares — an estimated $1.04M sold.

Blue Sky Asset Management first reported a position in NBIX in Q1 2017 and held it in 2 quarters. The position peaked at $1.21M in Q1 2017. 223 funds tracked by Wall St. Rank hold NBIX as of Q3 2017.

  • Blue Sky Asset Management reported no remaining Neurocrine Biosciences position as of Q3 2017 after selling out during the quarter.
  • Blue Sky Asset Management sold 22,710 Neurocrine Biosciences shares in Q3 2017, an estimated $1.04M.
  • Blue Sky Asset Management first reported a position in Neurocrine Biosciences in Q1 2017 and held it in 2 quarters.
  • Blue Sky Asset Management's Neurocrine Biosciences position peaked at $1.21M in Q1 2017.
  • 223 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2017.

Based on Blue Sky Asset Management's 13F filing for Q3 2017, filed 13 Nov 2017.